Press Release

BIORCHESTRA will present data on the therapeutic efficacy of their proprietary ASO against pathological miRNA, a key modulator of neuroinflammation and neurodegeneration, at the CTAD Meeting in Boston

Back to list BIORCHESTRA will present data on the therapeutic efficacy of their proprietary ASO against pathological miRNA, a key modulator of neuroinflammation and neurodegeneration, at the CTAD Meeting in…

Continue ReadingBIORCHESTRA will present data on the therapeutic efficacy of their proprietary ASO against pathological miRNA, a key modulator of neuroinflammation and neurodegeneration, at the CTAD Meeting in Boston

BIORCHESTRA appoints pharma veteran and Moderna and Akcea (Ionis) CMO “Dr. Louis St. L. O’Dea” as CMO of BIORCHESTRA

Back to list BIORCHESTRA appoints pharma veteran and Moderna and Akcea (Ionis) CMO "Dr. Louis St. L. O'Dea" as CMO of BIORCHESTRA BIORCHESTRA is a bio-tech company focused on the…

Continue ReadingBIORCHESTRA appoints pharma veteran and Moderna and Akcea (Ionis) CMO “Dr. Louis St. L. O’Dea” as CMO of BIORCHESTRA